President Trump blared about the “GREAT JOBS NUMBERS” from last week’s jobs report. But a deeper look at the data shows the U ...

AbbVie recently reported record 2025 results and outlined a stronger 2026 outlook, while advancing key immunology assets and ...

The company is down slightly this year, but that may be a buying opportunity.

The recent dip may have been an overreaction.

The product is priced at 95% below the brand-name cost. Ease of adoption. The product is FDA-designated as interchangeable and supported by innovative prescriber and patient engagement programs to ...

In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.

The expansion is expected to create 300 new jobs, including positions for engineers, scientists, manufacturing operators and lab technicians.

The total net revenues of AbbVie's Rinvoq and Skyrizi were about $25.87 billion in 2025, up 46.2% from 2024. Read why ABBV ...

The Chicago-based biopharmaceutical company AbbVie made a significant move on Feb. 23, as part of its broader commitment to ...

CAR-T therapies have changed the oncology space, but their cost and complexity have confined these treatments to specialized ...

A blockbuster drug is a best-selling medication earning over $1 billion annually. Learn about them and how they revolutionize ...

AbbVie leads today's top analyst picks after beating Q4 estimates, while RTX and IBM also draw attention for strong results and growth drivers.